Sofinnova Fund Sells $124M in Abivax Shares, Reducing Stake to 4.3%
ABVX has more than doubled off its 52-week low of $7.645.
Summary
Sofinnova Crossover I SLP, a significant institutional shareholder, sold approximately $124 million worth of Abivax shares and ADSs between June 30 and July 6, reducing its beneficial ownership to 4.3% of voting rights.
Key Events · Ownership and Investor Activity · ABVX
-
Significant Share Sales
Sofinnova Crossover I SLP, an institutional investor, sold approximately $124 million worth of Abivax shares and American Depositary Shares (ADSs) in open market transactions.
-
Stake Reduction
The fund's beneficial ownership decreased to 2,474,299 Ordinary Shares, representing approximately 4.3% of the company's outstanding voting rights.
-
Timing with Market Events
These sales occurred between June 30 and July 6, immediately following the company's positive Phase 3 trial results for obefazimod and an upsized $800 million public offering.
-
Profit Taking Near Highs
The transactions took place while Abivax's stock was trading near its 52-week high, indicating potential profit realization by the institutional investor.
Analysis · ABVX · Life Sciences
This Schedule 13D/A reports a substantial reduction in holdings by Sofinnova Crossover I SLP, an institutional investor. The fund sold over $124 million in shares and ADSs, representing more than 26% of its previous stake, coinciding with the company's recent positive Phase 3 trial results and a successful $800 million public offering. While institutional sales can be for portfolio rebalancing, the significant size and timing of these sales, especially near the stock's 52-week high, suggest profit-taking after a period of strong performance and capital infusion.
At the time of this filing, ABVX was trading at $144.66 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $12.3B. The 52-week trading range was $7.65 to $148.83. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.